SCHEMBL14840562

SCHEMBL14840562

Cc1ccc(C=O)c(-c2ccncc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
RECQL P46063 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CYP46A1 Q9Y6A2 2/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
ERN1 O75460 3/20 0.45
GAA P10253 1/20 0.41
CYP19A1 P11511 2/20 0.40
CYP11B2 P19099 2/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
AURKB Q96GD4 1/20 0.38
INCENP Q9NQS7 1/20 0.38
EIF4E P06730 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12060815 0.86 CYP46A1 (0.50) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL7930590 0.85 ALDH1A1 (0.43) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL28195991 0.81 PSMB5 (0.50) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL31195690 0.81 ERN1 (0.53) ALDH1A1KMT2AMAPTLMNACYP46A1
SCHEMBL14841074 0.79 ERN1 (0.45) ALDH1A1ERN1GAAGCGRMAPK14
SCHEMBL28195990 0.79 GRM2 (0.47) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL30405787 0.78 CYP1A1 (0.46) ALDH1A1MAPT
SCHEMBL19153327 0.78 ALDH1A1 (0.53) ALDH1A1ERN1CYP19A1CYP11B2MAPK14
SCHEMBL3422005 0.77 CYP46A1 (0.54) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL25871395 0.77 CYP46A1 (0.54) KDM4EALDH1A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-16 US disclosed
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2021-07-08 US disclosed
US-9440990-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-09-13 US disclosed
US-20150376205-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-31 US disclosed
US-8648079-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-11 US disclosed
US-20130090341-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376205-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, PSEN1, HTT KDM4E 376/4885ALDH1A1 59/4885KMT2A 454/4885
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 KDM4E 251/4885ALDH1A1 101/4885KMT2A 285/4885
US-20130090341-A1 HETEROCYCLIC COMPOUNDS HTT, NQO1, BDNF KDM4E 1584/4885ALDH1A1 300/4885KMT2A 331/4885
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 KDM4E 251/4885ALDH1A1 101/4885KMT2A 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.